ArticleChemMedChem2026
Identification and Optimization of a Truncated Hs-1-Derived Antimicrobial Peptide for Enhanced Broad-Spectrum Antiviral Activity.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs) represent promising scaffolds for the development of novel broad-spectrum antiviral therapeutics. Based on structural modeling data, we applied a systematic sequence downsizing approach to the 20-amino-acid AMP Hs-1 from Hypsiboas semilineatus to identify its minimal active region. A series of N- and C-terminally truncated derivatives was synthesized to preserve the predicted amphipathic α-helical core. Circular dichroism showed that the peptides adopt a random-coil conformation in aqueous solution and transition to an α-helical structure in hydrophobic environments, which is essential for membrane disruption. Antiviral screening against enveloped viruses revealed that the peptides interfere with the early stages of infection while maintaining a favorable safety profile. Notably, variant Hs-1[7-20] showed a two-to-four-fold potency enhancement over the parent peptide, indicating the successful removal of a detrimental N-terminal segment. Further optimization via N-terminal acetylation and C-terminal amidation yielded Hs-1[7-20]mod, which exhibited increased antiviral efficacy and serum stability, achieving low-micromolar IC50 values (0.5-0.7 µM) under virus pretreatment conditions while maintaining low toxicity (CC50 > 100 µM). In conclusion, Hs-1 was successfully optimized into a potent, stable, and safe antiviral candidate Hs-1[7-20]mod.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.